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Abstract
Objectives To compare the diagnostic accuracy and sensi-
tivity of Gd-EOB-DTPA MRI and diffusion-weighted
(DWI) imaging alone and in combination for detecting
colorectal liver metastases in patients who had undergone
preoperative chemotherapy.
Methods Thirty-two consecutive patients with a total of 166
liver lesions were retrospectively enrolled. Of the lesions,
144 (86.8 %) were metastatic at pathology. Three image sets
(1, Gd-EOB-DTPA; 2, DWI; 3, combined Gd-EOB-DTPA
and DWI) were independently reviewed by two observers.
Statistical analysis was performed on a per-lesion basis.
Results Evaluation of image set 1 correctly identified 127/
166 lesions (accuracy 76.5 %; 95 % CI 69.3–82.7) and 106/
144 metastases (sensitivity 73.6 %, 95 % CI 65.6–80.6).
Evaluation of image set 2 correctly identified 108/166
(accuracy 65.1 %, 95 % CI 57.3–72.3) and 87/144 metasta-
ses (sensitivity of 60.4 %, 95 % CI 51.9–68.5). Evaluation
of image set 3 correctly identified 148/166 (accuracy
89.2 %, 95 % CI 83.4–93.4) and 131/144 metastases (sen-
sitivity 91 %, 95 % CI 85.1–95.1). Differences were statis-
tically significant (P<0.001). Notably, similar results were
obtained analysing only small lesions (<1 cm).
Conclusions The combination of DWI with Gd-EOB-DTPA-
enhanced MRI imaging significantly increases the diagnostic
accuracy and sensitivity in patients with colorectal liver me-
tastases treated with preoperative chemotherapy, and it is
particularly effective in the detection of small lesions.
Key Points
• Accurate detection of colorectal liver metastases is essen-
tial to determine resectability.
• Almost 80 % of patients are candidates for neoadjuvant
chemotherapic treatment at diagnosis. After chemothera-
py, metastases usually decrease, and drug-induced liver
steatosis may be present.
• The sensitivity of imaging is significantly inferior to that in
chemotherapy-naïve patients.
• DWI combined with Gd-EOB-DTPA increases sensitivity
in detecting small metastases after chemotherapy.
Keywords Colorectal liver metastases . Chemotreated
patients . Gd-EOB-DTPA enhancedMRI . DWI . Small
lesions
Introduction
In patients with colorectal liver metastases (CLM), surgical
resection is still the only single treatment associated with a
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chance for cure [1]. Nevertheless, in recent years, the inte-
gration of surgery into multimodal treatment protocols has
resulted in 5-year survival rates approaching 60 % [2–4]. In
addition, although 80 % of patients are not considered to be
candidates for resection at the time of diagnosis [5], modern
chemotherapeutic regimens permit a number of patients to
have their disease converted from unresectable to resectable
[6, 7]. Therefore, accurate detection and localisation of all
metastatic deposits is essential to determine the resectability,
which is now defined solely according to the possibility to
obtain a radical (R0) resection [8]. However, staging the
liver disease after chemotherapy is more difficult, and the
sensitivity of preoperative imaging in such patients is sig-
nificantly inferior to that observed in chemotherapy-naïve
patients (CT: 65.3 % versus 87.5 %; PET 49 % versus
93.3 %, respectively) [9]. This has been attributed to the
aspect of post-chemotherapy metastases that often have
reduced contrast in respect to the liver and ill-defined bor-
ders [9]. Although these morphological characteristics
might simply be the consequence of a decrease in tumour
size to sub-centimetre diameters, frequently they are deter-
mined by a drug-induced steatosis [10], which modifies the
imaging aspect of the liver parenchyma.
Thus, to improve the detection rate, novel contrast media
and new imaging techniques should be utilised. In a previ-
ous study we reported that the accuracy and sensitivity of
contrast-enhanced magnetic resonance (MRI) were signifi-
cantly higher than those of spiral computed tomography
(CT), with the largest difference observed in the detection
of metastatic lesions of less than 1 cm [11]. In addition, we
recently demonstrated the possibility to increase the MRI
detection rate by using the liver-specific MRI contrast agent
gadoxate disodium (Gd-EOB-DTPA) in the subset of
patients who had undergone chemotherapy (83.2 % versus
64.5 % of CT respectively) [12].
Diffusion-weighted MRI (DWI) is sensitive to the mo-
lecular diffusion of water in biologic tissues, and recent
technical advancements have permitted obtaining high-
quality DWI images of the liver. Colorectal liver metastases
show high signal restricted diffusion on DWI compared
with normal liver parenchyma. Using breath-hold single
shot echo-planar (EPI) DWI with parallel imaging, Koh et
al. [13] improved the mangafodipir trisodium MR imaging
sensitivity and diagnostic accuracy. Nevertheless, robust
evidence supporting the routine use of DWI is still lacking,
in particular in the subset of chemo-treated patients with
small metastatic lesions. Therefore, the purpose of this study
was to determine the current role of DWI in the most
challenging subset of patients, i.e. those treated with neo-
adjuvant or conversion chemotherapy, by comparing the
diagnostic accuracy of Gd-EOB-DTPA MR imaging, DWI
imaging and the combination of Gd-EOB-DTPA MR and
DWI imaging in detecting colorectal liver metastases.
Methods
Study population
In the last 5 years, all patients evaluated at our institution for
potentially resectable colorectal liver metastases had a thor-
ough preoperative workup including a thoraco-abdominal
CT and a Gd-EOB-DTPA-enhanced liver MRI. In all con-
secutive individuals in whom (1) a pathologically proven
adenocarcinoma of the colon or rectum and (2) at least one
liver lesion with CT characteristics diagnostic of liver me-
tastasis, (3) treated with neoadjuvant or conversion chemo-
therapy, MRI was performed according to a specific
protocol (see MRI protocol) including DWI sequences. All
patients gave their informed consent before any imaging
study. Between August 2009 and July 2011, 146 patients
were resected for colorectal liver metastases. Out of these
patients, 32 were eventually considered eligible for enrol-
ment into the current study. Data collection and analysis
were performed according to the national legislation and
institutional guidelines conforming to the ethical standards
of the Helsinki Declaration.
MRI protocol
MR examinations were performed using a 1.5-T MR system
(Achieva, Philips Medical Systems) employing a SENSE
body coil. Before contrast medium administration the fol-
lowing sequences, whose acquisition parameters are
derailed in Table 1, were performed.
– Breath-hold T1-weighted axial section turbo spin-echo,
in phase and out of phase; 40 sections through the liver
were acquired in two 20-s breath-hold data acquisitions.
– Breath-hold T2-weighted axial sections, single shot; 27
sections through the liver were acquired in a 13-s
breath-hold data acquisition.
– Breath-hold balanced weighted axial sections, turbo
field echo; 36 sections through the liver were acquired
in a 13-s breath-hold data acquisition.
– Triggered T2-weighted axial sections, turbo spin echo,
high resolution; 30 sections through the liver were
acquired in about 2 min 30 s.
– Breath-hold T2-weighted coronal sections, turbo spin
echo; 25 sections through the liver were acquired in a
21-s data acquisition.
– SENSE DWI, axial section spin-echo, using two gra-
dients, b value 0 0, 300, 600 and b value0800 s/mm2;
27 sections through the liver were acquired in two 40-s
data acquisitions.
Then, a dynamic study was performed by 3D T1-
weighted gradient echo sequences (THRIVE); 70 sections
through the liver were acquired in about 1 min before and
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after Gd-EOB-DTPA intravenous injection (dose of 0.1 ml/
kg) during arterial (30″), portal (70″) and early hepatobiliary
phase (120″) phases; 20 min after contrast medium admin-
istration, during the hepatospecific phase, 3D T1-weighted
gradient echo sequences were performed (Fig. 1).
Image interpretation and analysis
Two radiologists with 20 (SC) and 9 (MP) years of experi-
ence in abdominal MRI and hepatobiliary expertise inde-
pendently reviewed all images without knowledge of any
Table 1 MRI acquisition











T1 (in and out of phase) 146 4.3 and
2.6
405 168/256 2 4, gap 1
T2 axial single-shot 12,615 100 415 260/400 64 7, gap 1
BALANCED TFE 3.6 1.8 405 319/336 130 5, gap 1
T2 axial triggered 2,084 100 375 244/512 130 6, gap 1
T2 coronal TSE 10,302 100 375 204/384 130 6, gap 1
DWI (b00, 300, 600, 800) 4,092 0.0(63) 415 160/288 51 7, gap 1




5.1 2.5 405 199/512 60 6, gap 3
Fig. 1 Metastases slightly/not
identified on CT (a, c) and well
defined and detected on Gd-
EOB-DTPA MRI (b, d)
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clinical details. The MRI findings of metastatic lesions were
then compared with permanent histopathology, which was
our gold standard. Notably, the final tumour staging and the
definitive type and extent of resection were defined on the
basis of intraoperative ultrasound. In all patients all sus-
pected metastatic lesions were removed. Therefore, only
clear benign lesions (cysts and angiomas) at intraoperative
ultrasound remained unresected. Three different sets of
images were reviewed on a workstation during three sepa-
rate readings sessions, with a 1-month interval between
readings. Image sets were as follows:
– Image set 1: Unenhanced T1-/T2-weighted images were
evaluated with Gd-EOB-DTPA-enhanced MRI images.
– Image set 2: Unenhanced T1-/T2-weighted images were
evaluated with DWI images.
– Image set 3: Combined Gd-EOB-DTPA and DWI im-
age set: Unenhanced T1-/T2-weighted images were
assessed with Gd-EOB-DTPA-enhanced MRI and
DWI images.
Focal liver lesions identified at review of each image set
were assessed by individual observers for lesion (1) site (the
location of each lesion was recorded. An anatomical de-
scription and slice position of each lesion were also noted
to facilitate subsequent lesion matching and comparison);
(2) size (the largest axial diameter of each lesion was mea-
sured in millimetres); and (3) characteristics (a lesion was
deemed metastatic if it showed low T1 signal intensity,
heterogeneous and slightly variable high T2 signal intensity,
appeared hypointense 20 min after contrast administration
and had high signal intensity on DWI images) (Fig. 2). In
case of discrepancies between readers in the identification
and localisation of lesions, the MRIs were re-evaluated by
both readers together in a reading session.
Statistical analysis
The primary endpoint of the study was the overall diagnos-
tic accuracy, defined based on per-lesion analysis, as the
sum of true-positive and true-negative results. Of note, we
evaluated only metastatic lesions that were the sole lesions
that were systematically removed. Secondary endpoints
were sensitivity, specificity, and positive and negative pre-
dictive value (PPV and NPV) on a per-lesion basis. Results
were reported as point estimates and 95 % confidence inter-
vals (95% CIs). The effect of the size of the lesion on the
sensitivity of image sets was assessed using the chi-square
test for trend, whereas the comparison between values of
sensitivity and specificity of the image sets was performed
using the McNemar test. Differences were considered
Fig. 2 Metastasis appearance
on T1-weighted (a), T2-
weighted (b) and during hepa-
tospecific phase imaging (c)
and DWI (d)
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significant at a P-value of <0.05. Statistical analysis was
performed using SAS software version 9.1.
Results
In all, 32 consecutive patients [24 male and 8 female;
median age 65 years, (range 45–78)] were eventually
operated on and formed the study cohort. A total of 166
lesions were detected. Of these, 144 (86.7 %) were
metastases, whereas the remaining 22 (13.3 %) were
considered, at intraoperative ultrasound, as benign
lesions (cysts and/or angiomas), albeit for these latter
lesions a histological diagnosis was not available. The
median size of the metastatic lesions was 9 mm, rang-
ing from 2 to 80 mm; 75 lesions (52.1 %) were smaller
than 1 cm, 37 (25.7 %) were in the range of 10–
20 mm, and the remaining 32 (22.2 %) were bigger
than or equal to 20 mm. Most lesions were located in
the right lobe.
Image set 1 correctly identified 127 out of 166 lesions
(accuracy: 76.5 %; 95% CI 69.3–82.7 %), 106 out of 144
metastases (sensitivity 73.6 %; 95 % CI 65.6–80.6 %) and
21 out of 22 benign lesions (specificity 95.4 %; 95 % CI
77.2–99.9 %). The 38 missed lesions had a median diameter
of 5 mm, ranging from 2 to 10 mm. Sensitivity increased
from 52.7 % for lesions sized <10 mm to 100 % for those
measuring ≥20 mm (P<0.0001). There was only one false-
positive result for a PPVof 99.1 % (106/107, 95 % CI 94.9–
100 %) and a NPVof 35.6 % (21/59, 23.6–49.1 %) (Figs. 3,
4 and 5).
Image set 2 correctly identified 108 out of 166 lesions
(accuracy: 65.1 %; 95 % CI 57.3–72.3 %), 87 out of 144
metastases (sensitivity 60.4 %; 95 % CI 51.9–68.5 %) and
21 out of 22 benign lesions (specificity 95.4 %; 95% CI
77.2–99.9 %). The 38 missed lesions had a median diameter
of 5 mm, ranging from 2 to 11 mm. Sensitivity increased
from 33.3 % for lesions sized <10 mm to 100 % for those
measuring ≥20 mm (P<0.0001). There was only one false
positive. Therefore, the PPV was 98.9 % (87/88 95 % CI
93.8–1.00 %), whereas the NPV was 26.9 % (21/78, 17.5–
38.2 %) (Figs. 3, 4, 5).
Image set 3 correctly identified 148 out of 166 lesions
(accuracy: 89.2 %; 95 % CI 83.4–93.4 %), 131 out of 144
metastases (sensitivity 91.0 %; 95 % CI 85.1–95.1 %) and
17 out of 22 benign lesions (specificity 77.3 %; 95 % CI
54.6–92.2 %). The 13 missed lesions had a median diameter
of 4 mm, ranging from 3 to 6 mm. Sensitivity increased
from 83.3 % for lesions sized <10 mm to 100 % for those
measuring ≥20 mm (P00.001). There were five false pos-
itives; thus, the PPV was 96.3 % (131/136, 95% CI 91.6–
98.8 %), whereas the NPV was 56.7 % (21/78, 17.5–
38.2 %) (Figs. 3, 4, 5).
The diagnostic accuracy of set 3 is significantly better
than that in both set 1 and set 2 (P<0.0001). The sensitivity
of set 1 is significantly better than that in set 2 (P00.003).
Consistent results have been found for sensitivity. Table 2
summarises the reported results.
Fig. 3 Metastasis detected on
imaging sets 1, 2 and 3. This
lesion was indentified on T1-
weighted (a), T2-weighted (b),
DWI (c) and during hepatospe-
cific phase imaging (d)
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Fig. 4 This is an example of
how DWI with unenhanced
images can be difficult to
interpret. In this image DWI
identifies an hyperintense area
(c) not detected on T1-weighted
and T2-weighted images. Dur-
ing the hepatospecific phase
(d), it is clear that this area cor-
responds to a biliary structure
Fig. 5 This figure
demonstrates how combined
assessment of DWI and Gd-
EOB-DTPA imaging (c, d) is
useful in detecting a small me-
tastasis not identified on T1-
weighted and T2-weighted im-
aging (a, b)
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Discussion
The current study demonstrates that, in patients who
have undergone chemotherapy for colorectal liver me-
tastases, assessment of diffusion-weighted sequences
increases the diagnostic accuracy and sensitivity of
Gd-EOB-DTPA-enhanced MRI sequences (Fig. 6).
Despite advances in medical treatments and ablative
therapies, liver resection remains the mainstay of treat-
ment of colorectal liver metastases. Thus, accurate de-
tection and precise localisation of all metastatic deposits
within the liver are essential to determine resectability
and the overall surgical strategy (i.e. one- or two-stage
hepatectomy). In recent years, however, the efficacy of
the newer cytotoxic agents has expanded the use of
systemic chemotherapy in the preoperative setting be-
fore liver resection in both unresectable and resectable
patients [14–16]. As a consequence, post-chemotherapy
evaluation has become a routine challenge. In particular,
while assessment of the tumour response using dimen-
sional criteria [17] is relatively easy, a precise preoper-
ative mapping might be problematic, especially in
patients with multiple small lesions. Yet, this likely
represents the key factor for improving patient selection
and true radical resections. Difficulties in restaging the
liver disease after chemotherapy derive from various
aspects. Firstly, treated lesions often exhibit reduced
contrast in respect to the liver parenchyma and ill-
defined borders [9] as a consequence of a decrease in
tumour size to sub-centimetre diameters or of a drug-
induced steatosis [10], which modifies the imaging as-
pect of the liver parenchyma. Secondly, patients often
commence chemotherapy without high-quality pre-
treatment imaging used for comparison. Therefore, tiny
lesions might be missed. In such cases, one might judge
a patient for whom a radical resection might not other-
wise be feasible to be resectable. To avoid unnecessary
laparotomy, strategies to improve the preoperative de-
tection rate have been investigated. We previously dem-
onstrated that the accuracy and sensi t ivi ty of
mangafodipir-trisodium MRI are significantly higher
than those of spiral CT, with the largest difference
observed in the detection of metastatic lesions of less
than 1 cm [12]; nevertheless, in such patients the sen-
sitivity was still low (67.7 %).
Therefore, since 2006 we have routinely favoured
MRI in the assessment of liver disease. Use of the
liver-specific MRI contrast agent Gd-EOB-DTPA has
further increased the detection rate [13] and thus our
diagnostic accuracy. In the present study we focussed
on DWI. In particular, we investigated whether the
diagnostic accuracy and sensitivity, which inversely
Table 2 Diagnostic capability
of the three image sets
In parentheses: 95 %
confidence intervals
DWI-MRI Contrast-enhanced MRI Contrast-enhanced MRI + DWI
Diagnostic
accuracy
65.1 % (57.3–72.3) 76.5 % (69.3–82.7) 89.2 % (83.4–93.4)
Sensitivity
Overall 60.4 % (51.9–68.5) 73.6 % (65.6–80.6 %) 91.0 % (85.1–95.1)
Size <10 mm 33.3 % (22.9–45.2) 52.0 % (40.2–63.7) 81.3 % (70.7–89.4)
Size 10–20 mm 81.1 % (64.8–92.0) 94.6 % (81.8–99.3) 100 % (90.5–100)
Size ≥20 mm 100 % (89.1–100) 100 % (89.1–100) 100 % (89.1–100)
Specificity 95.4 % (77.2–99.9 %) 95.4 % (77.2–99.9) 77.3 % (54.6–92.2)
PPV 98.9 % (93.8–100 %) 99.1 % (94.9–100) 96.3 % (91.6–98.8)
NPV 26.9 % (17.5–38.2 %) 35.6 % (23.6–49.1) 56.7 % (37.4–74.5)
Fig. 6 Combined assessment
of Gd-EOB-DTPA imaging (a)
and DWI (b) has greater sensi-
tivity in identifying lesions
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correlate with the number and size of liver metastases,
can be further improved by the combination of DWI
and Gd-EOB-DTPA-enhanced MRI sequences. The most
important finding of our study is that the combined
assessment has greater diagnostic accuracy and sensitiv-
ity (89.2 % and 91 %, respectively) compared to those
of each individual method. The observation that assess-
ment of DWI was particularly important in identifying
small lesions, which may be missed or misinterpreted as
peripheral vasculo-biliary structures or artifacts in
contrast-enhanced sequences (Fig. 7), was noteworthy.
Previous studies have suggested that the combination of
DWI with hepatospecific contrast-enhanced sequences
may improve our ability to detect colorectal liver me-
tastases [13–18]. However, these data were obtained in
small, heterogenous series. Our data are more robust
since we analysed an almost two-fold larger series of
colorectal liver metastases in an homogeneous popula-
tion of patients. In addition, our study is the first to
report results in the most challenging group of patients,
i.e. those treated with preoperative chemotherapy
[19–22]. By focussing only on this group of patients
we selected individuals with more complex liver disease
such as those with multiple small bilateral liver metas-
tases. This underscores the importance of our findings
and explains why we reported an overall sensitivity
value of 73.6 %, which is slightly inferior to that
reported in the literature (81–91 % [23]). Rather, our
sensitivity of 73.6 % should be regarded as remarkable
when considering that more than 50 % of the hepatic
lesions were smaller than 1 cm and that all patients had
a preoperative course of systemic chemotherapy, which
may cause liver injuries. Image set 2 had low sensitivity
in the detection of colorectal liver metastases. DWI with
unenhanced images can be difficult to interpret because
of the inherent problems in distinguishing vascular and
biliary structures from small metastases and because this
sequence has a low spatial resolution. Although in de-
signing our study we felt it necessary to include this
image set, we are aware that in clinical practice this set
of images is not used. One of the limitations of this
study is the absence of pathological characterisation of
all suspected benign lesions. Nevertheless, intraoperative
ultrasound is so accurate in identifying benign lesions,
specifically cysts or haemangiomas, that we can assume
that none of the lesions considered non-malignant were
otherwise. In support of this, after a median follow-up
of 13 months, none of the benign lesions proved to be
metastatic at follow-up imaging.
Therefore, we believe that DWI should be routinely com-
bined with contrast-enhanced MRI sequences, especially in
patients with multiple small lesions treated with preoperative
chemotherapy. The future challenge will be to further increase
the detection rate with a parallel increase in specificity.
Fig. 7 These images show how
DWI is especially useful in
identifying small lesions (a and
b, c and d)
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